Barricaid is designed to prevent reherniation and reoperation for patients with large annular defects after lumbar discectomy, according to a news release. It has been used in more than 10,000 patients and is supported by clinical studies.
“This new coverage policy will give Cigna members access to the Barricaid technology and help to reduce the burden of reherniation and reoperation for discectomy patients when deemed medically necessary by their surgeo,” Intrinsic Therapeutics founder Greg Lambrecht said in the release.
The new Cigna policy went into effect June 15.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
